Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $47.5 million.

  • Editas Medicine's Accumulated Expenses rose 6509.29% to $47.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.5 million, marking a year-over-year increase of 6509.29%. This contributed to the annual value of $45.9 million for FY2024, which is 3268.23% up from last year.
  • According to the latest figures from Q3 2025, Editas Medicine's Accumulated Expenses is $47.5 million, which was up 6509.29% from $48.1 million recorded in Q2 2025.
  • Editas Medicine's Accumulated Expenses' 5-year high stood at $48.1 million during Q2 2025, with a 5-year trough of $14.6 million in Q3 2021.
  • Its 5-year average for Accumulated Expenses is $29.3 million, with a median of $28.8 million in 2024.
  • In the last 5 years, Editas Medicine's Accumulated Expenses crashed by 2822.67% in 2021 and then soared by 9991.13% in 2023.
  • Editas Medicine's Accumulated Expenses (Quarter) stood at $20.2 million in 2021, then soared by 54.99% to $31.3 million in 2022, then grew by 10.44% to $34.6 million in 2023, then surged by 32.68% to $45.9 million in 2024, then rose by 3.63% to $47.5 million in 2025.
  • Its Accumulated Expenses was $47.5 million in Q3 2025, compared to $48.1 million in Q2 2025 and $47.5 million in Q1 2025.